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Chronic kidney disease (CKD) is associated with fatal
cardiovascular consequences in part due to ectopic
calcification of soft tissues particularly arteries, capillaries,
and cardiac valves. An increasing body of evidence
from experimental studies and in vivo data suggest that
(I) a mineral imbalance with hyperphosphatemia and
high-circulating calciumphosphate product, (II) a
deficiency of systemic or local calcification inhibitors,
(III) death or ‘damage’ of vascular smooth muscle cells
(VSMCs), and/or (IV) phenotypic transformation of VSMCs
to osteo/chondrocytic cells may all act in concert to initiate
and sustain vascular calcification. In CKD patients inhibitory
systems are overwhelmed by a multitude of agents that
induce VSMC damage and cell death resulting in the release
of vesicles capable of nucleating basic calcium phosphate.
Studies with genetically altered mice have identified both
local and systemic calcification inhibitors that act to maintain
VSMC differentiation or regulate vesicle properties. However,
for many of these proteins the mechanisms and sites of
action are still under investigation. In particular, it is unclear
whether factors present in the circulation have an inhibitory
role there and whether circulating levels of these proteins
influence or are indicative of underlying disease processes in
individual patients. A greater understanding of the origins
and roles of potential circulating inhibitors may result in
novel strategies aimed at the prevention or reversal of the
life-limiting calcifying vasculopathies seen in CKD patients.
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Cardiovascular disease is the most common cause of death
in patients with chronic kidney disease (CKD) with a 30-fold
higher mortality than the general population despite
adjustment for traditional cardiovascular risk factors such
as diabetes mellitus and hypertension.1 Recent epidemio-
logical studies have shown that even minimal alterations in
renal function (as evidenced by a reduced glomerular filtra-
tion rate, presence of microalbuminuria, and elevated serum
phosphate levels in the general population) pose potent
cardiovascular risks.2,3 Vascular calcification is a significant
contributor to cardiovascular risk in CKD patients, and
its extent and severity has been correlated with mortality in
several studies.4
Calcification of arteries occurs in the intima in association
with atherosclerosis, where it may contribute to plaque
formation and rupture, and in the media, where it causes
vascular stiffening. Although a combination of intimal and
medial calcification may occur in patients with CKD, either
process may occur independently of the other, and, at least
in adolescents and young adults with CKD, the vascular
‘calcium load’ is almost exclusively medial. Increased arterial
stiffness is mechanistically linked with systolic hypertension,
left ventricular hypertrophy, and reduced coronary perfusion,
and is a significant independent predictor of mortality.5
Direct evidence of the calcification burden is obtained from
plain X-ray or, in recent years, from cardiac computed tomo-
graphy (CT) scans (electron beam CT or helical/multislice
CT). However, neither can differentiate between medial
and intimal calcification and, as both tests measure overt
calcification only, they are not sensitive enough to measure
early vascular calcium load. The ability to identify and
quantitate early vascular calcification in patients initiating
dialysis may allow us to predict their likelihood of developing
accelerated calcification and would have implications for
their treatment regime. This has become particularly relevant
as the 4D study has shown that statins are ineffective in
reducing cardiovascular events in diabetic patients with
CKD, and the availability of non-calcium-based phosphate
binders like sevelamer and lanthanum carbonate can allow
for treatments that are less likely to contribute to the calcium
load for patients susceptible to progression of calcification.
As an alternative to the currently available imaging methods,
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the use of circulating biomarkers may be a useful and
convenient measure of an individual patient’s susceptibility
to calcify. Evidence is accumulating to suggest that relevant
biomarkers might include a subset of circulating proteins
that have been shown to act as inhibitors of vascular smooth
muscle cell (VSMC) calcification.
VASCULAR CALCIFICATION IS A HIGHLY REGULATED
PROCESS
Vascular calcification was previously thought to be a passive
process caused by precipitation of mineral from the circu-
lation, particularly in patients with a mineral imbalance.
However, as early as the 19th century, Virchow described
bone-like structures in the vasculature, which provided
the first clue that vascular calcification may be a regulated
process. More recent studies have described true bone
marrow, osteo/chondrocytic cells, cytokines, transcription
factors, matrix proteins, and matrix vesicles characteristic of
mature osteoblasts and terminally differentiated chondro-
cytes within calcified lesions, with the inorganic material
being hydroxyapatite, the same mineral found in physiologic
biomineralization.4 Local VSMCs as well as circulating
mesenchymal stem cells, local pericytes, and fibroblasts that
exhibit multilineage potential may transdifferentiate into
osteo/chondrocytic cells in the arterial wall and orchestrate
bone formation and calcification. The osteo/chondrocytic
conversion of VSMCs and stem cells both in vitro and in vivo
is accompanied by upregulation of Cbfa1/Runx2, osterix,
Msx2, and Sox9 transcription factors that are centrally
involved in chondrocyte maturation and osteoblastic differ-
entiation. Accumulating evidence suggests that multiple
factors such as hypertension, reactive oxygen species, advan-
ced glycation end products, lipids, inflammatory proteins,
such as tumor necrosis factor-a, and potentially other,
as yet unidentified, damage-inducing agents initiate osteo/
chondrocytic conversion and matrix vesicle release in
VSMCs. However, in CKD, a mineral imbalance is central
to this damage with elevated phosphate inducing expression
of Runx2 and osterix in VSMCs. More significantly, apop-
totic bodies and matrix vesicles similar to those that nucleate
mineral in bone are released from dying and damaged
VSMCs and nucleate mineral in vascular tissues.6 Elevated
calcium induces VSMC death and increases matrix vesicle
release, whereas calcium and phosphate both increase the
mineralization potential of the released matrix vesicles.
Finally, in concert with this phenotypic change and damage,
VSMCs lose expression of endogenous mineralization inhi-
bitors, further accelerating their osteo/chondrocytic con-
version as well as reducing their capacity to limit the
mineralization process (Figure 1).
Animal models with targeted disruption of genes as well
as in vitro studies have been central in identifying naturally
occurring inhibitors of calcification (Table 1). Fetuin-A
(a2-Heremans-Schmid glycoprotein)
7 is a serum protein
produced in the liver that exerts its inhibitory effects via
the circulation. However, many proteins such as matrix
Gla protein (MGP),8 Smad6,13 nucleotide pyrophosphatase/
phosphodiesterase-1 (NPP1),12 Klotho,10 and osteoprotegerin
(OPG)9 are expressed locally by VSMCs in the healthy vessel
wall. Interestingly, a number of these inhibitors are concen-
trated in VSMC-derived matrix vesicles where they act to
block mineral nucleation. Moreover, they also find their way
into the circulation where they can be measured, suggesting
that they may have actions both locally and within the
circulation. In the remainder of this review, we explore the
evidence that inhibitory proteins function within the circula-
tion, and the possibility that their circulating levels may
inform us of underlying disease processes.
CIRCULATING INHIBITORS
Fetuin-A
All extracellular fluid contains calcium and phosphate in
concentrations exceeding their solubility product for sponta-
neous precipitation, suggesting that under normal conditions
protein inhibitors of ectopic soft tissue calcification prevent
the development or progression of vascular calcification.
In vitro studies have shown that, whereas serum from normal
subjects is a potent inhibitor of VSMC calcification, serum
from CKD patients lacks this protective effect.6 Although this
might be due to the presence of toxins in uremic serum,
an alternate explanation may be that serum from dialysis
patients lacks inhibitors, and fetuin-A is a paradigm for
this model. Fetuin-A belongs to the cystatin superfamily
of proteins, is made predominantly by the liver, and acts as
a negative acute phase reactant; its production is therefore
downregulated in systemic inflammation. Fetuin-A/ mice
exhibit mild ectopic calcification, but extensive mineraliza-
tion can be induced in almost all soft tissues when crossed
onto a DBA/2 calcification-susceptible mouse strain or when
these mice are fed on a mineral- and vitamin D-rich diet or
on high-fat diet.7 Fetuin-A acts systemically by binding excess
mineral and inhibiting basic calcium phosphate precipitation
in serum and extracellular fluids,7 and is also found in the
circulation of rats complexed to bone-derived hydroxyapatite
(the ‘fetuin-mineral complex’), which may represent another
protective mechanism to limit deposition of mineral in the
vasculature.14 Importantly, fetuin-A is a multifunctional
protein that in addition to its systemic effects can also modu-
late the calcification processes locally. At sites of vascular
damage it is taken up by VSMCs, incorporated into intra-
cellular vesicles, and then released within matrix vesicles
where it potently inhibits mineral nucleation. In addition,
fetuin-A inhibits VSMC apoptosis and aids in phagocytosis of
extracellular vesicles, thus further limiting mineralization.15
In vivo, systemic fetuin-A levels are significantly lower in
hemodialysis patients than in healthy controls, possibly as a
result of low-grade inflammation induced by dialysis.16
Moreover, polymorphisms in the fetuin-A gene correlate
with circulating levels of phosphate, suggesting that genetic
variants resulting in changes in fetuin-A protein function
may predispose some patients to calcification.17 However,
fetuin-A only partially accounts for some of the capacity of
Kidney International (2008) 73, 384–390 385
M Schoppet et al.: Vascular calcification in CKD t r a n s l a t i o n a l n e p h r o l o g y
serum to inhibit calcification, suggesting that other as yet
unidentified serum proteins can also inhibit calcification.
Although some of these, like the closely related protein
fetuin-B and albumin, are likely to be serum proteins not
previously considered as regulators of calcification, other
candidates include calcification inhibitors produced in soft
tissues or bone that are also present in the circulation
(Table 2). Some proteins such as MGP have been identified as
a component of the ‘fetuin-mineral complex’ described in
rats and are also concentrated in kidney stones suggesting
that they can be absorbed from serum and then bind to
calcified structures. However, as discussed below, evidence
that these proteins have a regulatory role in serum remains
controversial.
MGP
MGP, a low-molecular-weight protein found in bone, carti-
lage, and highly expressed in kidney, cardiac valves, and the
media of arteries, contains five residues of the vitamin
K-dependent amino acid g-carboxyglutamic acid (Gla).
Warfarin, commonly used in hemodialysis patients, inhibits
the vitamin-K-dependent g-carboxylation of MGP and is
potentially a risk factor for the development of calciphylaxis.
MGP/ mice have inappropriate calcification of cartilage
and die within weeks after birth due to rupture of their
heavily calcified aorta.8 Within calcified vessels, cartilaginous
metaplasia occurs, which may be related to the ability
of MGP to bind bone morphogenetic protein-2 (BMP2): lack
of MGP leads to increased BMP2 activity, which is likely to
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Figure 1 | Soft tissue calcification, vascular calcification, and bone loss are common features of the pathology in CKD patients.
These processes are driven by common mechanisms of damage, vesicle release, and loss of mineralization regulating proteins both locally
and systemically. An understanding of how these processes are related is just beginning to emerge. The origins, effects, and potential of
circulating mineralization regulators to act as biomarkers of disease are key areas for further investigation. Ca, calcium; FGF23, fibroblast
growth factor-23; MGP, matrix Gla protein; NPP1, nucleotide pyrophosphatase-1; OPG, osteoprotegerin; P, phosphate; PPi, inorganic
pyrophosphate; PTH, parathyroid hormone; VSMC, vascular smooth muscle cell.
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induce VSMC chondrocytic conversion. MGP is also found
in matrix vesicles, wherein it acts like fetuin-A to limit
mineral nucleation, and it is also present in serum.6 However,
transgenic studies have shown that rescue of calcification
only occurs if MGP is expressed in VSMCs, not if it is only
present systemically.33 Thus, the role of MGP in the
circulation, if any, remains largely unknown, and although
MGP gene polymorphisms may be a prognostic factor for the
progression of cardiovascular disease in CKD patients,22 to
date MGP has not proved to be a good circulating marker of
calcification. Although some studies have shown that serum
MGP is a risk factor for atherosclerosis, associations between
circulating MGP levels and coronary artery calcification have
given conflicting results.34,35 However, it may be that we are
measuring the ‘wrong’ MGP. A recent study has shown that
in healthy arteries MGP deposition was associated with
elastic fibres in the tunica media, with no undercarboxylated
MGP present. In contrast, in vessels with intimal and/or
medial calcification, undercarboxylated MGP was localized
around all areas of calcification, suggesting that impaired
carboxylation of MGP, potentially due to warfarin use or low
vitamin K status, is associated with intimal and medial
vascular calcification.20 Moreover, the incorporation of
undercarboxylated MGP in matrix vesicles increases their
capacity to calcify. Thus, circulating MGP levels may indeed
be a biomarker of VSMC damage and calcification, but it
may be necessary to measure undercarboxylated MGP serum
levels, and these have not been assessed so far.
OPG
OPG is a soluble decoy receptor for the principal regulator of
osteoclasts, receptor activator of nuclear factor-kB ligand
(RANKL), which stimulates all aspects of osteoclast biology
including differentiation, activation, fusion, and survival. By
blocking RANKL, OPG inhibits bone resorption, but OPG is
also expressed in a variety of cells and tissues, especially in the
media of arteries. Targeted deletion of the OPG gene in mice
resulted not only in osteoporosis, but also in calcification of
the great arteries (aorta, renal arteries) without vascular
challenge. Calcification in these mice could be rescued by
introduction of an opg transgene from mid-gestation but not
by parenteral application of OPG after mineralized lesions
were established; this is in contrast to osteoporosis, which
could be efficiently treated by a parenteral OPG regimen.9
Thus, although the precise role of OPG in the vascular wall
and its possible interaction with VSMCs has yet to be
determined, like MGP it does not appear to function if
present only systemically. Interestingly, although OPG is
deposited at sites of calcification and globally downregulated
in the diseased vasculature, circulating OPG levels are
increased in patients on hemodialysis, and have been linked
to the presence and extent of coronary artery disease.9 Given
that OPG is produced by a variety of cell types, the source of
elevated OPG remains elusive and it is unclear whether
increased systemic OPG levels reflect the cause or conse-
quence of vascular calcification or are not associated at all. It
is interesting to speculate that circulating OPG may in itself
be a damaging agent for VSMCs in a manner analogous to
glucose in diabetes and PTH in CKD. Clearly, further studies
are required to determine the effects of elevated OPG on
VSMC function.
Premature aging-related genes: Klotho and FGF23
These two multifunctional proteins regulate calcium phos-
phate metabolism as well as aging, and deletion studies have
shown that they play a role in vascular calcification. Klotho is
a pleiotrophic transmembrane protein that is thought to
repress intracellular signaling of insulin and insulin-like
growth factor-1 (IGF1). It also acts as a cofactor for the
fibroblast growth factor (FGF) receptor 1c in FGF23 signaling
in what appears to be an evolutionarily conserved mechanism
acting to suppress aging. Recent studies have shown that
Klotho- and FGF23-deficient mice show similar phenotypes,
including hyperphosphatemia and hypercalcemia, in addition
Table 1 | Gene disruption studies in mice with a phenotype of vascular calcification
Gene Vascular phenotype, affected vessels
Present in VSMC
vesicles
Fetuin-A (a2-Heremans-
Schmid glycoprotein)
Ectopic calcification of small blood vessels, most organs (e.g., myocardium, lung, kidney, skin)a7 Yes
Matrix Gla protein (MGP) Medial calcification of arteries, aortic valves (not arterioles, capillaries, or veins), cartilaginous
metaplasia within the vessel wall8
Yes
Osteoprotegerin (OPG) Medial and subintimal calcification of the aorta and renal arteries, presence of multinuclear
osteoclast-like cells within the vascular wall9
c
Klotho All calibers of arteries affected, intimal thickening of medium-sized arteries10 c
Fibroblast growth factor-23
(FGF23)
Vascular calcification in kidneys11 c
Nucleotide
pyrophosphatase/
phosphodiesterase-1 (NPP1)
Aortic medial calcification, intraaortic cartilaginous differentiation of VSMCs12 c
Madh6b Cartilaginous metaplasia and ossification of the media of larger vessels, hyperplasia of cardiac
valves13
c
VSMC, vascular smooth muscle cell.
aOn a DBA/2 genetic background or a mineral/vitamin D-rich diet.
bEncodes Smad6 protein.
cPresence in VSMC-derived vesicles not tested.
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to premature aging disorders such as arteriosclerosis,
osteoporosis, and skin atrophy.10,11 The vascular phenotype
of these mice resembles the age-related disorder Mo¨ncke-
berg’s medial sclerosis in humans, with extensive medial
calcification of all calibers of arteries. The bone system shows
a low turnover osteoporosis, with decreased osteoblasts and
osteoclasts, resembling senile osteoporosis.10 FGF23-null
mice have severe growth retardation, osteopenia, a markedly
short life span, renal phosphate wasting, and also excessive
mineralization in soft tissues with marked vascular calcifica-
tion in the kidneys.11 Additionally, both proteins can be
detected in serum, but their role in the circulation has not
been determined, and, so far, direct actions of Klotho and
FGF23 on VSMC function have not been demonstrated.
Table 2 | Calcification regulators identified in the circulation (separate document)
Factor Role in circulation Levels in circulation
Human single gene defects or genetic
polymorphisms
Fetuin-A (a2-Heremans-Schmid
glycoprotein)
Inhibitor Reduced in CKD16 Polymorphisms may predispose patients
to vascular calcification18
Albumin Inhibitora Low serum albumin in CKD, predicts
cardiovascular events and morbidity19
a
Matrix Gla protein (MGP) No effectb Conflicting results for serum levels in
vascular calcification20
Keutel syndrome-extensive vascular
calcification and abnormal calcification
of cartilage21
MGP gene polymorphisms may be
prognostic for vascular calcification22
Osteoprotegerin (OPG) a Increased in CKD and patients with
vascular calcification9
Juvenile Paget’s disease-an autosomal-
recessive osteopathy, but no clear
association with vascular disease9
Polymorphisms in the promoter region of
OPG are associated with atherosclerosis9
Receptor activator of NF-kB
ligand (RANKL)
Inducera Increased in CKD23 and serum levels may
be a predictor of vascular risk
a
Klotho a Decline with agea Polymorphism may be a genetic risk factor
for coronary artery disease24
Fibroblast growth factor-23 (FGF23) a Increased in CKD25 a
Inorganic pyrophosphate (PPi) Inhibitor
a Reduced in CKD, and also removed by
hemodialysis26
Infantile idiopathic arterial calcification—
calcification of the internal elastic laminae
of large vessels, often with death in the
first year of life4
Bone morphogenetic protein-2
(BMP2)
Inducera Increased in CKDa a
Bone morphogenetic protein-7
(BMP7)
Inhibitora a a
Osteopontin (OPN) Inhibitora Increased in CKD,27 conflicting results for
serum levels in vascular calcification
Sequence variation associated with
carotid intima-media thickness28
Osteocalcin (OC) No effectb No clear correlation between glomerular
filtration rate and serum osteocalcin,
lower serum levels in vascular disease29
a
Bone-specific alkaline
phosphatase
a Increased in CKD23 and vascular
calcification30
a
Mineral and hormonal regulators
Calcium (Ca) Inducer Increased in CKD, risk factor for
cardiovascular events in dialyzed patients1
a
Phosphate (P) Inducer Increased in CKD and vascular calcification3 a
Magnesium (Mg) Inhibitor Inverse relationship between serum
magnesium and vascular calcification
in CKD31
a
Parathyroid hormone (PTH) Inducer/inhibitor Increases Ca absorption and influences
bone turnover,1 direct effect on VSMCsa
a
Vitamin D Inducer/inhibitor Promotes increased Ca and P absorption
from the gut, increases Ca uptake by VSMCs,
reduces VSMC migration and differentiation,
anti-inflammatory effect, and negative
regulation of the
renin–angiotensin–aldosterone system32
a
Vitamin K Inhibitor Promotes g-carboxylation of MGP and
reduces calcification20
a
CKD, chronic kidney disease; NF-kB, nuclear factor-kB; VSMC, vascular smooth muscle cell.
aNot known.
bNo effect seen in animal models.
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NPP1
The enzyme NPP1 hydrolyzes ATP to generate inorganic
pyrophosphate (PPi), a physicochemical inhibitor of hydro-
xyapatite crystal growth. VSMCs constitutively express this
calcification inhibitor within the normal aortic wall, and
NPP1/ mice develop medial calcification of the aorta with
cartilaginous metaplasia, suggesting PPi may act to inhibit
this aberrant differentiation. The phenotype of animals is
reminiscent of idiopathic infantile arterial calcification,
linked to heritable NPP1 deficiency, and characterized by a
severe and frequently lethal condition of widely disseminated
arterial calcification with mineralization of the internal elastic
lamina.12 In vitro studies have shown that vascular damage
induces the expression of alkaline phosphatase that inacti-
vates PPi locally and thus facilitates calcification.
36 However,
PPi is also found in the circulation and may exert its effects
on many tissues via this conduit, although so far no experi-
mental evidence exists to support this possibility. In hemo-
dialysis patients PPi levels are reduced,
26 and PPi is also
cleared by dialysis, suggesting that altered PPi metabolism
could contribute to vascular calcification in this group.
BMP signaling
BMPs are multifunctional cytokines originally identified as
having diverse biological functions in bone remodeling and
osteogenesis, but have since been found to play a role in
multiple tissues. Some, including BMP7, which is necessary
for normal kidney development, are also found at high levels
in the circulation. Intracellular BMP signals are transduced
by Smad proteins, with Smad6 and Smad7 acting as major
negative regulators. Smad6 is not found in the circulation,
but is expressed in the vasculature, predominantly in larger
vessels, the same sites that exhibit cartilaginous metaplasia
and ossification in the medial layer after targeted deletion of
Madh6, the gene that encodes for Smad6.8 Therefore,
inhibitory Smad6 seems to limit the osteogenic responsive-
ness of cardiovascular cells to BMP signals to inhibit vascular
calcification. Loss of Smad6 or an imbalance in local and
circulating BMPs is thus likely to influence the progression of
vascular calcification. This is important because circulating
BMPs may be bound in serum by proteins such as MGP and
thus a balance between circulating concentrations of a
number of interacting proteins may be important for health.
Indeed, administration of systemic BMP7 restores skeletal
anabolic balance, reduces serum phosphate levels, and
thereby reduces vascular calcification in experimental animal
models of CKD. BMP7 is expressed primarily in the kidney
and its expression levels are reduced in CKD.37 Thus, further
exploration of the role of this and other circulating BMPs in
humans is likely to be informative.
CONCLUSIONS
The devastating effects of CKD on the vasculature are the net
result of multiple pathogenic mechanisms that overwhelm
natural defenses against calcification. Circulating toxic ele-
ments that cause VSMC damage and death accumulate while
calcification inhibitors are decreased both locally and systemi-
cally. Studies in animal models have provided important
insights into the pathogenesis of vascular calcification, but
approaches to stop progression or even reverse the pathology
are in their infancy. One key area for further investigation is
the role of circulating proteins in regulating calcification, either
by effects on maintenance of calcium phosphate homeostasis
in solution or by direct effects on vascular cell function. It is
likely that there are a number of as yet undiscovered circulating
inhibitors that may be crucial in inhibiting calcification.
The relationship between vascular calcification and bone
homeostasis is also crucial, as inhibitors may exert differential
effects in these tissues. Moreover, some circulating inhibitors
and activators such as osteocalcin and alkaline phosphatase
are produced by bone, and their levels are used as indicators
of bone turnover, but whether they exert effects on soft tissue
calcification is unknown. Additionally, it will be crucial to
determine whether circulating proteins are complexed with
serum or other proteins that limit their function. More
speculatively, it will be important to determine if circulating
inhibitors are complexed with hydroxyapatite from bone or,
more importantly, circulate in vesicles released from VSMCs.
Other key questions such as the tissue origins of circulating
proteins, the impact of perturbations in their circulating
levels on VSMC function, and whether changes in levels
can predict calcification, all need to be explored further.
Importantly, mechanisms of calcification are likely to be
similar in all soft tissues, and kidney calcification may be one
mechanism promoting progression of kidney failure. There-
fore it is tempting to speculate that it may be possible to
measure and globally limit the susceptibility of a patient to
calcify by directly influencing what’s circulating.
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